Research theme for competitive and other funds (6):
2023 - 2026 変異受容体型チロシンキナーゼの細胞内輸送制御による白血病治療薬の開発研究
2022 - 2025 治癒を目指したCML幹細胞の特性解析
2020 - 2023 多発性骨髄腫の病態形成に関わる抗腫瘍免疫機構の解析研究
2018 - 2021 Characterization molecular and immunologic features of CML stem cells for treatment-free remission.
2016 - 2019 Analysis of novel pathogenesis caused by disorder of immature hematopoietic cells in multiple myeloma
2015 - 2018 Development of novel anti-leukemic therapy targeting clathrin-dependent endocytosis
Show all
Papers (119):
Kensuke Usuki, Toshihiro Miyamoto, Takuji Yamauchi, Kiyoshi Ando, Yoshiaki Ogawa, Masahiro Onozawa, Takahiro Yamauchi, Hitoshi Kiyoi, Akira Yokota, Takayuki Ikezoe, et al. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. International journal of hematology. 2024. 119. 6. 647-659
Takahiro Haeno, Shinya Rai, Yoshiaki Miyake, Maiko Inoue, Ko Fujimoto, Aki Fujii, Yoshio Iwata, Shuji Minamoto, Takahide Taniguchi, Hiroaki Kakutani, et al. Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma. Journal of clinical and experimental hematopathology : JCEH. 2023. 63. 2. 99-107
Ryosuke Fujiwara, Yasuhiro Taniguchi, Shinya Rai, Yoshio Iwata, Aki Fujii, Ko Fujimoto, Takahiro Kumode, Kentaro Serizawa, Yasuyoshi Morita, J Luis Espinoza, et al. Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. Biochemical and biophysical research communications. 2022. 626. 156-166
Yasuyoshi Morita, Yasuhito Nannya, Motoshi Ichikawa, Hitoshi Hanamoto, Hirohiko Shibayama, Yoshinobu Maeda, Tomoko Hata, Toshihiro Miyamoto, Hiroshi Kawabata, Kazuto Takeuchi, et al. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. International journal of hematology. 2022. 116. 5. 659-668
Chikashi Yoshida, Takeshi Kondo, Tomoki Ito, Masahiro Kizaki, Kazuhiko Yamamoto, Toshihiro Miyamoto, Yasuyoshi Morita, Tetsuya Eto, Yuna Katsuoka, Naoki Takezako, et al. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. International journal of hematology. 2022. 116. 1. 89-101